Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

2011 Scrip 100: Experimental collaboration model to drive Merck cancer research

This article was originally published in Scrip

Executive Summary

In May 2010, Merck & Co launched an oncology collaborative trials network (Onconet) with leading international cancer research centres to speed up the development of its drug and vaccine candidates. The global research sites will lead the design and conduct of Phase 0 to Phase IIa clinical studies of Merck's investigational oncology candidates. Merck says that every year, the network will enrol approximately 1,200 patients in 30 to 40 clinical trials.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC011296

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel